Shanghai Henlius (复宏汉霖) IPO: Valuation of Four Biosimilars
Shanghai Henlius, a clinical-stage pharmaceutical company back by Fosun Pharma, is seeking a listing in Hong Kong. In our previous insight, we have...
886 Views
Mabpharm IPO Preview: Mixed Prospects of Phase 3 Drug Candidates
MabPharm (2181 HK) is a pre-revenue biopharmaceutical company in China with a focus on drugs and biosimilars for cancers and autoimmune diseases....
584 Views
ECM Weekly (18 April 2019) - Duiba Group, MabPharm, Huami, Cofco Meat, Innovent, Times China
Aequitas Research puts out a weekly update on the deals that have been covered by Smartkarma Insight Providers recently, along with updates for...
861 Views
Innovent Biologics (信达生物) Placement - Selling upon Lock-Up Expiry
Undisclosed shareholders of Innovent Biologics Inc (1801 HK) is looking to sell part of its stake (36.2m shares, about US$125m) in the company. The...
878 Views
Keytruda Approved for Lung Cancer Treatment in China - A Review of PD-1 Battle Field
Anti-PD-1 monoclonal antibody (mAb) is a hotly contested immunotherapy area in China, with seven companies working on clinical trials covering...
620 Views